A Phase 3 interventional study of Evolocumab and Placebo in Dyslipidemia, sponsored by Amgen. Completed at 417 sites in 30 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-01-16.
Sponsored by Amgen · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing evolocumab in Dyslipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Dyslipidemias.
Among the 10 studies testing evolocumab in Dyslipidemias, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 3rd registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 10 studies testing evolocumab in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,974 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 409 across the 10 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 9 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing evolocumab in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
Participants who were enrolled in study 20110118 (FOURIER; NCT01764633) at select sites in select countries (selected based on study start-up timelines) were invited to participate in this cognitive function study, 20130385. There was no separate randomization for Study 20130385; data were analyzed according to Study 20110118 randomized treatment arm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.
Drug: Placebo · Drug: Background Statin Therapy
Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.
Biological: Evolocumab · Drug: Background Statin Therapy
Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Also known as: AMG 145, Repatha
Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score
Assessments were performed with the Cambridge Neuropsychological Test Automated Battery (CANTAB), a language-independent battery of computerized tests that is used to assess cognitive function. The Spatial Working Memory (SWM) test assesses the cognitive domain of executive function (high-level thinking and decision making). Patients search for colored tokens hidden inside boxes on the screen by touching them. The critical instruction is that once a token has been found inside a box, there will never be a token hidden inside that box again, so patients must not return to a box where a token has been found. The SWM strategy index of executive function represented the number of times a subject began a search with a different box. The Z score represents the standardized measure of how far an individual subject deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.
Time frame: Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).
Mean Change From Baseline in Spatial Working Memory (SWM) Between-errors Z Score
Assessments were performed with the CANTAB, a language-independent battery of computerized tests that is used to assess cognitive function. The Spatial Working Memory (SWM) between-errors test assesses the cognitive domain of working memory (holding material in mind while that material is being actively processed). Patients search for colored tokens hidden inside boxes on the screen by touching them. The critical instruction is that once a token has been found inside a box, there will never be a token hidden inside that box again, so patients must not return to a box where a token has been found. The SWM between-errors score is the number of times that a patient revisited a box in which a token had previously been found. The Z score represents the standardized measure of how far an individual participant deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.
Time frame: Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).
Mean Change From Baseline in Paired Associated Learning (PAL) Total Errors Adjusted Z Score
The CANTAB PAL test assesses visuospatial episodic memory (storing/retrieving information by associating an event with a time and place). Boxes on the screen opened up one at a time to reveal a number of patterns. Participants were asked to remember the location of each pattern. After all the boxes had been opened, each pattern was then shown in the center of the screen in a randomized order, and the patient should touch the box where they think each pattern was hidden. The PAL total errors adjusted comprised the number of errors committed by a patient plus an adjustment for the estimated number of errors the patient would have made on any stages that were not reached. Z score represents the standardized measure of how far an individual patient deviates from the study cohort average at baseline. A higher Z score indicated better performance. The mean change from baseline averaged across all the visits is reported.
Time frame: Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).
Mean Change From Baseline in Reaction Time (RTI) Median 5-choice Reaction Time Z Score
Assessments were performed with the CANTAB, a language-independent battery of computerized tests that is used to assess cognitive function. The Reaction Time (RTI) test assessed the cognitive domain of psychomotor speed (detecting and responding to a stimulus). Participants held down a button until a spot appeared in 1 of 5 circles on the screen. As soon as possible after the spot flashed up, the patient lifted their finger from the button and touched the circle in which the spot appeared. The RTI median 5-choice reaction time was the median duration between the onset of the stimulus and the release of the button. Z score represents the standardized measure of how far an individual participant deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.
Time frame: Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).
Participants enrolled in Study 20110118 (FOURIER; NCT01764633) at select sites in select countries (based on study start-up timelines) were invited to participate in this cognitive function study. Participants were enrolled at 340 centers in 29 countries in Europe, North America, and Asia Pacific from September 2014 to July 2015.
| Milestone | Placebo | Evolocumab |
|---|---|---|
| Started | 990 | 984 |
| Received treatment | 990 | 983 |
| Completed | 968 | 953 |
| Not completed | 22 | 31 |
| Withdrew: Withdrawal by subject | 21 | 31 |
| Withdrew: Lost to follow-up | 1 | 0 |
Assessments were performed with the Cambridge Neuropsychological Test Automated Battery (CANTAB), a language-independent battery of computerized tests that is used to assess cognitive function. The Spatial Working Memory (SWM) test assesses the cognitive domain of executive function (high-level thinking and decision making). Patients search for colored tokens hidden inside boxes on the screen by touching them. The critical instruction is that once a token has been found inside a box, there will never be a token hidden inside that box again, so patients must not return to a box where a token has been found. The SWM strategy index of executive function represented the number of times a subject began a search with a different box. The Z score represents the standardized measure of how far an individual subject deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.
| Z score | Placebo | Evolocumab |
|---|---|---|
| Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score | 0.1206 (0.0535 to 0.1877) | 0.1134 (0.0449 to 0.1820) |
Assessments were performed with the CANTAB, a language-independent battery of computerized tests that is used to assess cognitive function. The Spatial Working Memory (SWM) between-errors test assesses the cognitive domain of working memory (holding material in mind while that material is being actively processed). Patients search for colored tokens hidden inside boxes on the screen by touching them. The critical instruction is that once a token has been found inside a box, there will never be a token hidden inside that box again, so patients must not return to a box where a token has been found. The SWM between-errors score is the number of times that a patient revisited a box in which a token had previously been found. The Z score represents the standardized measure of how far an individual participant deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.
| Z score | Placebo | Evolocumab |
|---|---|---|
| Mean Change From Baseline in Spatial Working Memory (SWM) Between-errors Z Score | 0.1024 (0.0373 to 0.1675) | 0.0691 (0.0026 to 0.1355) |
The CANTAB PAL test assesses visuospatial episodic memory (storing/retrieving information by associating an event with a time and place). Boxes on the screen opened up one at a time to reveal a number of patterns. Participants were asked to remember the location of each pattern. After all the boxes had been opened, each pattern was then shown in the center of the screen in a randomized order, and the patient should touch the box where they think each pattern was hidden. The PAL total errors adjusted comprised the number of errors committed by a patient plus an adjustment for the estimated number of errors the patient would have made on any stages that were not reached. Z score represents the standardized measure of how far an individual patient deviates from the study cohort average at baseline. A higher Z score indicated better performance. The mean change from baseline averaged across all the visits is reported.
| Z score | Placebo | Evolocumab |
|---|---|---|
| Mean Change From Baseline in Paired Associated Learning (PAL) Total Errors Adjusted Z Score | 0.1098 (0.0511 to 0.1686) | 0.0873 (0.0273 to 0.1472) |
Assessments were performed with the CANTAB, a language-independent battery of computerized tests that is used to assess cognitive function. The Reaction Time (RTI) test assessed the cognitive domain of psychomotor speed (detecting and responding to a stimulus). Participants held down a button until a spot appeared in 1 of 5 circles on the screen. As soon as possible after the spot flashed up, the patient lifted their finger from the button and touched the circle in which the spot appeared. The RTI median 5-choice reaction time was the median duration between the onset of the stimulus and the release of the button. Z score represents the standardized measure of how far an individual participant deviates from the study cohort average at baseline. A higher Z score reflects better performance. The mean change from baseline averaged across all the visits is reported.
| Z score | Placebo | Evolocumab |
|---|---|---|
| Mean Change From Baseline in Reaction Time (RTI) Median 5-choice Reaction Time Z Score | 0.0153 (-0.0529 to 0.0834) | -0.0575 (-0.1270 to 0.0121) |
Collected over From the first dose of study drug to the end of study. The median duration of follow-up was 19.4 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 204/990 (20.6%) | 257/990 (26%) |
| Evolocumab | — | 212/983 (21.6%) | 272/983 (27.7%) |
| Event | Placebo | Evolocumab |
|---|---|---|
| Angina pectorisCardiac disorders | 16/990 | 15/983 |
| Angina unstableCardiac disorders | 15/990 | 11/983 |
| Atrial fibrillationCardiac disorders | 7/990 | 13/983 |
| Non-cardiac chest painGeneral disorders | 12/990 | 6/983 |
| PneumoniaInfections and infestations | 7/990 | 10/983 |
| Peripheral arterial occlusive diseaseVascular disorders | 5/990 | 10/983 |
| HypertensionVascular disorders | 5/990 | 7/983 |
| Carotid artery stenosisNervous system disorders | 5/990 | 6/983 |
| Peripheral ischaemiaVascular disorders | 4/990 | 6/983 |
| AnaemiaBlood and lymphatic system disorders | 6/990 | 2/983 |
| Event | Placebo | Evolocumab |
|---|---|---|
| NasopharyngitisInfections and infestations | 74/990 | 101/983 |
| HypertensionVascular disorders | 66/990 | 61/983 |
| Upper respiratory tract infectionInfections and infestations | 63/990 | 53/983 |
| Diabetes mellitusMetabolism and nutrition disorders | 59/990 | 45/983 |
| Back painMusculoskeletal and connective tissue disorders | 36/990 | 58/983 |
Demographic data are provided for all enrolled participants. Baseline Cambridge Neuropsychological Test Automated Battery (CANTAB®) data are provided for all dosed participants enrolled in the study with a baseline cognitive function assessment prior to or on the first dose date of study drug and ≥ 1 post-baseline cognitive measure.
| Age, Continuous(years) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 62.7 ± 8.7 | 62.9 ± 8.7 | 62.8 ± 8.7 |
| Sex: Female, Male(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Female | 274 | 269 | 543 |
| Male | 716 | 715 | 1431 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 9 | 23 |
| Not Hispanic or Latino | 976 | 975 | 1951 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 28 | 31 | 59 |
| Black or African American | 32 | 28 | 60 |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | 3 |
| White | 910 | 908 | 1818 |
| Multiple | 1 | 1 | 2 |
| Other | 17 | 12 | 29 |
| Spatial Working Memory (SWM) Strategy Index of Executive Function Raw Score(units on a scale) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 17.8 ± 3.4 | 17.8 ± 3.5 | 17.8 ± 3.4 |
| Spatial Working Memory (SWM) Strategy Index of Executive Function Z Score(Z score) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | -0.0106 ± 0.9910 | 0.0166 ± 1.0066 | 0.0026 ± 0.9983 |
| Spatial Working Memory Between Errors Raw Score(units on a scale) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 21.0 ± 10.6 | 20.9 ± 10.2 | 21.0 ± 10.4 |
| Spatial Working Memory Between Errors Z Score(Z score) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | -0.0130 ± 1.0075 | 0.0024 ± 0.9675 | -0.0055 ± 0.9879 |
4 further baseline measures are reported on the registry.
Showing the first 100 of 417 sites across 30 countries. Choose a country and city above to see the rest.
Ran from Sep 2014 to primary completion in Nov 2016, 26 months.
Results were first posted in Jan 2018, 1 year 2 months after primary completion. A results delay was requested in Jun 2017.
Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 26 months is above that.
Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab